Downloads: 1012

Files in This Item:
File Description SizeFormat 
s00280-013-2151-8.pdf450.42 kBAdobe PDFView/Open
Title: A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin) in cancer patients.
Authors: Kanai, Masashi  kyouindb  KAKEN_id
Otsuka, Yoshihiko
Otsuka, Kazunori
Sato, Maremi
Nishimura, Takafumi
Mori, Yukiko  kyouindb  KAKEN_id
Kawaguchi, Michiya
Hatano, Etsuro
Kodama, Yuzo  kyouindb  KAKEN_id
Matsumoto, Shigemi  kyouindb  KAKEN_id
Murakami, Yoshiki
Imaizumi, Atsushi
Chiba, Tsutomu
Nishihira, Jun
Shibata, Hiroyuki
Author's alias: 金井, 雅史
Keywords: Curcumin
Bioavailability
Theracurmin®
Gemcitabine
Pancreatic cancer
Issue Date: Jun-2013
Publisher: Springer-Verlag
Journal title: Cancer chemotherapy and pharmacology
Volume: 71
Issue: 6
Start page: 1521
End page: 1530
Abstract: A growing number of preclinical studies have demonstrated that curcumin could be a promising anticancer drug; however, poor bioavailability has been the major obstacle for its clinical application. To overcome this problem, we developed a new form of curcumin (Theracurmin) and reported high plasma curcumin levels could be safely achieved after a single administration of Theracurmin in healthy volunteers. In this study, we aimed to evaluate the safety of repetitive administration of Theracurmin in cancer patients.
Rights: The final publication is available at Springer via http://dx.doi.org/10.1007/s00280-013-2151-8
この論文は出版社版でありません。引用の際には出版社版をご確認ご利用ください。This is not the published version. Please cite only the published version.
URI: http://hdl.handle.net/2433/189888
DOI(Published Version): 10.1007/s00280-013-2151-8
PubMed ID: 23543271
Appears in Collections:Journal Articles

Show full item record

Export to RefWorks


Export Format: 


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.